Russell Investments Group Ltd. Lowers Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Russell Investments Group Ltd. decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Rating) by 13.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 198,969 shares of the company’s stock after selling 31,878 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.40% of Protagonist Therapeutics worth $2,171,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new position in shares of Protagonist Therapeutics during the 1st quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Protagonist Therapeutics by 18.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,536 shares of the company’s stock valued at $93,000 after acquiring an additional 1,337 shares during the last quarter. Quantbot Technologies LP bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at $76,000. Jane Street Group LLC increased its holdings in Protagonist Therapeutics by 273.3% in the 3rd quarter. Jane Street Group LLC now owns 10,289 shares of the company’s stock valued at $87,000 after acquiring an additional 7,533 shares during the last quarter. Finally, Arizona State Retirement System bought a new stake in Protagonist Therapeutics in the 4th quarter valued at $113,000. Hedge funds and other institutional investors own 91.51% of the company’s stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock opened at $26.05 on Monday. The company’s 50-day moving average price is $22.73 and its 200-day moving average price is $15.69. Protagonist Therapeutics, Inc. has a twelve month low of $6.91 and a twelve month high of $26.87.

Protagonist Therapeutics (NASDAQ:PTGX – Get Rating) last posted its earnings results on Wednesday, March 15th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.02). As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. JMP Securities reduced their price target on shares of Protagonist Therapeutics from $31.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 16th. StockNews.com assumed coverage on shares of Protagonist Therapeutics in a report on Thursday. They issued a “sell” rating on the stock. Finally, HC Wainwright lifted their price target on shares of Protagonist Therapeutics from $33.00 to $38.00 and gave the company a “buy” rating in a report on Thursday, March 16th.

About Protagonist Therapeutics

(Get Rating)

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.